Abstract: The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having diameters of about 1 to about 1,000 microns. The stable shaped particles of the present invention are particularly well-suited to the fabrication of pharmaceutical formulations, particularly where sustained release and uniform bioavailability are desired. The storage stable particles are formed by a solid state crystallization of allotropic organic compounds. The solid state crystallization process of the present invention affords a means for achieving a storage stable crystalline form of said allotropic compound without loss or deterioration of the original particle dimensions.
Type:
Grant
Filed:
July 12, 2000
Date of Patent:
March 25, 2003
Inventors:
John-Claude Savoir, Juan Angeles, Aurelio De Gyves, Abraham Gomez
Abstract: The present invention relates to microcapsules with an aqueous core containing at least one water-soluble cosmetic or dermatological active principle, and with a polymeric and/or waxy envelope, in which the said envelope consists
of at least one polymer chosen from polycaprolactone, poly(3-hydroxybutyrate), poly(ethylene adipate), poly(butylene adipate), cellulose esters of at least one C1-C4 carboxylic acid, copolymers of styrene and of maleic anhydride, copolymers of styrene and of acrylic acid, styrene-ethylene/butylene-styrene block terpolymers, styrene-ethylene/propylene-styrene block terpolymers and terpolymers of ethylene, of vinyl acetate and of maleic anhydride, and/or
of at least one wax chosen from beeswax, polyglycerolated beeswax, hydrogenated plant oils, paraffin with a melting point above 45° C., and silicone waxes.
Abstract: The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having diameters of about 1 to about 1,000 microns. The stable shaped particles of the present invention are particularly well-suited to the fabrication of pharmaceutical formulations, particularly where sustained release and uniform bioavailability are desired. The storage stable particles are formed by a solid state crystallization of allotropic organic compounds. The solid state crystallization process of the present invention affords a means for achieving a storage stable crystalline form of said allotropic compound without loss or deterioration of the original particle dimensions.
Type:
Grant
Filed:
May 23, 2001
Date of Patent:
March 4, 2003
Inventors:
John-Claude Savoir, Juan Angeles, Aurelio De Gyves, Abraham Gomez
Abstract: The invention relates to a stable fumagillin formulation and to the method of use thereof in treating and/or combating intestinal infections.
Abstract: Disclosed is a sustained release system that includes a polymer and a prodrug having a solubility less than about 1 mg/ml dispersed in the polymer. Advantageously, the polymer is permeable to the prodrug and may be non-release rate limiting with respect to the rate of release of the prodrug from the polymer. This permits improved drug delivery within a body in the vicinity of a surgery via sustained release rate kinetics over a prolonged period of time, while not requiring complicated manufacturing processes.
Type:
Application
Filed:
April 26, 2002
Publication date:
February 27, 2003
Inventors:
Jianbing Chen, Paul Ashton, Thomas J. Smith
Abstract: A biocompatible intermolecular polymer complex comprises an anionic component and a non protein cationic component. The anionic component comprises a linear or branched polysaccharide chain wherein at least 5% of the basic structural units are glucuronic acid. The cationic component comprises a linear or branched natural, semi-synthetic or synthetic oligomer or polymer.
Type:
Application
Filed:
January 19, 2001
Publication date:
February 27, 2003
Inventors:
Ivan Santar, Frantisek Kiss, Jiri Briestensky
Abstract: Bioerodible polyorthoesters useful as orthopedic implants or vehicles for the sustained delivery of pharmaceutical, cosmetic and agricultural agents contain amine functionalities and &agr;-hydroxy acid-containing groups.
Abstract: A sustained/prolonged release pharmaceutical dosage form is disclosed. The form comprises a hard shell capsule and a formulation comprising (a) a water insoluble medicament, (b) a high melting fatty ester, (c) a low viscosity oil, (d) a cellulosic polymer, and (e) a non-ionic surfactant.
Type:
Grant
Filed:
February 21, 2001
Date of Patent:
February 25, 2003
Assignee:
Kos Pharmaceuticals, Incorporated
Inventors:
Jose Gutierrez-Rocca, Josephine Dunne, Saul A. Rios
Abstract: The present invention relates to a nutritional supplement which comprises two different iron compounds, namely a rapidly dissolving iron compound and a slowly dissolving iron compound. The tablet is particularly contemplated for administration to women as a prenatal supplement, during pregnancy, and during lactation. Methods of alleviating iron deficiency and diseases and disorders associated therewith are also disclosed.
Type:
Grant
Filed:
March 31, 2000
Date of Patent:
February 18, 2003
Assignee:
Warner Chilcott Laboratories Ireland Limited
Abstract: Sustained release dosage forms of sertraline which release sertraline at a rate between 1 mgA/hr and 40 mgA/hr. The dosage forms may exhibit an initial delay period during which sertraline is released at a rate less than 1 mgA/hr.
Type:
Grant
Filed:
September 7, 1999
Date of Patent:
February 11, 2003
Assignee:
Pfizer Inc.
Inventors:
Mary Tanya Am Ende, William John Curatolo, Hylar Lewis Friedman, Dwayne Thomas Friesen, Scott Max Herbig, Ravi Mysore Shankar, James Blair West
Abstract: This invention relates to bioenhanced formulations comprising eprosartan or eprosartan mesylate in the amorphous form, a process for its production, compositions containing the compound and methods of using the compound to block angiotensin II receptors and to treat hypertension, congestive heart failure and renal failure.
Abstract: This invention relates to carvedilol methanesulfonate, compositions containing this compound and methods of using carvedilol methanesulfonate to treat hypertension, congestive heart failure and angina.
Abstract: The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.
Type:
Grant
Filed:
July 16, 2001
Date of Patent:
February 4, 2003
Assignee:
Sanofi-Synthelabo
Inventors:
Gérard Alaux, Gareth Lewis, Frédéric Andre
Abstract: A device for the sustained release in vivo of a water soluble, biologically active agent wherein the agent is susceptible to aggregation comprising a drug delivery device and aggregation-stabilized, biologically active agent wherein the aggregation-stabilized agent is disposed within the drug delivery device.
Type:
Grant
Filed:
September 22, 1997
Date of Patent:
February 4, 2003
Assignee:
Alkermas Controlled Therapeutics, Inc.
Inventors:
Paul A. Burke, Stephen E. Zale, Mark A. Tracy, OluFunmi Lily Johnson, Howard Bernstein, M. Amin Khan, Henry E. Auer
Abstract: An osmotic delivery system for controlled delivery of a beneficial agent includes an implant capsule having a beneficial agent reservoir, an osmotic agent which expands on contact with fluid imbibed through a permeable membrane retained by the implant capsule, a delivery port, and a valve for opening and closing the delivery port. When the osmotic agent expands, a pressure is exerted against a separating member positioned between the beneficial agent reservoir and the osmotic agent. The separating member moves within the capsule, thereby forcing the valve to move a distance such that the beneficial agent can exit the reservoir through the delivery port.
Abstract: The present invention provides elastomeric copolyester amides, elastomeric copolyester urethanes, and methods for making the same. The polymers that are based on &agr;-amino acids and possess suitable physical, chemical and biodegradation properties. The polymers are useful as carriers of drugs or other bioactive substances.
Abstract: The present invention relates to a method for preparation of plant extract powder and oral compositions containing plant extract powder prepared by the same. More particularly, the present invention could provide a method for preparation of plant extract powder comprising the steps of (a) loading a plant extract having activities of prevention of and treatment for periodontal diseases or tooth decay into a porous powder carrier; (b) coating said carrier's surface with a water-insoluble coating agent and oral compositions containing plant extract powder prepared by the above described method which have an excellent periodontal diseases preventing effect and tooth decay preventing effect.
Type:
Grant
Filed:
May 3, 2001
Date of Patent:
January 7, 2003
Assignee:
Pacific Corporation
Inventors:
Hyun Soo Moon, Byung Ryeul Lee, Key Hyun Lee
Abstract: Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.
Type:
Grant
Filed:
August 14, 2000
Date of Patent:
December 31, 2002
Assignee:
Peirce Management, LLC
Inventors:
Kamal K. Midha, Mark Hirsh, Whe-Yong Lo
Abstract: A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration—time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.
Type:
Grant
Filed:
October 4, 2001
Date of Patent:
December 31, 2002
Assignee:
Eurand Pharmaceuticals Ltd.
Inventors:
Phillip J. Percel, Krishna S. Vishnupad, Gopi M. Venkatesh
Abstract: The present invention concerns a composition containing a cholesterol lowering component such as &bgr;-sitosterol and/or &bgr;-sitostanol in a monomolecular, low associated or “cluster” form, where a melt and/or solution of the said components are distributed, immobilised and stabilised in a matrix; food containing such a composition and a method of preparing this composition.
Abstract: The present invention relates to novel, orally administered compositions comprising two redox systems: reduced ascorbic acid in a sustained release form and oxidized isoquercetin with an increased concentration of reduced vitamin C over a prolonged time in the brain. These compositions are useful as neuroprotective agents possessing preventive properties against memory dysfunctions.
Abstract: A controlled release pharmaceutical formulation is disclosed. The formulation comprises a construct having a matrix of a material selected from the group comprising (a) a high melting point fatty acid ester, (b) an oil, (c) a polymeric cellulose derivative and (d) a mixture of any of the foregoing. Associated with the matrix is a selected medicament. Preferably, the matrix comprises at least two of the aforementioned materials or components.
Abstract: The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.
Abstract: The invention is directed to pharmaceutical compositions useful in the treatment of migraine. The compositions contain metoclopramide and one or more NSAIDs in unit dosage form. By selecting NSAIDs that are non-acidic or segregating the metoclopramide and NSAID, the storage life of the compositions has been increased. Also disclosed are coordinated dosage forms for the sequential release of drugs. The invention encompasses methods of treating migraine using any of these dosage forms.
Type:
Grant
Filed:
March 3, 2000
Date of Patent:
November 12, 2002
Assignee:
Pozen Inc.
Inventors:
John R. Plachetka, Zakauddin T. Chowhan
Abstract: A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram metformin, once daily, may be achieved while providing effective control of plasma glucose.
Type:
Grant
Filed:
September 16, 1999
Date of Patent:
November 5, 2002
Assignee:
Bristol-Myers Squibb Co.
Inventors:
Peter Timmins, Andrew B. Dennis, Kiren A. Vyas
Abstract: Oral dosage forms are provided for the administration of a bisphosphonic acid compound in the prevention and treatment of conditions involving calcium or phosphate metabolism, i.e., conditions associated with bone resorption such as osteoporosis, Paget's disease, periprosthetic bone loss, osteolysis, malignant hypercalcemia, metastatic bone disease, multiple myeloma, and periodontal disease. The dosage forms are either enterically coated capsules housing the drug in a liquid or semi-solid carrier, or enterically coated osmotically activated drug delivery devices.
Abstract: An antibiotic product, in particular a betalactam such as cephalosporin (in particular cefuroxime and/or cefpodoxime) or a penicillin (in particular axmoxicillin or dicloxacillin) is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
Type:
Application
Filed:
December 20, 2001
Publication date:
September 26, 2002
Inventors:
Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
Abstract: An antibiotic product, in particular a fluroquinilone such as ciprofloxacin, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
Type:
Application
Filed:
December 20, 2001
Publication date:
September 26, 2002
Inventors:
Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
Abstract: An antibiotic product, in particular a tetracycline, such as doxycycline, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.
Type:
Application
Filed:
December 20, 2001
Publication date:
September 26, 2002
Inventors:
Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Sandra E. Wassink
Abstract: A controlled release microcapsulate pharmaceutical formulation for burst-free, sustained, programmable release of hydrophocib bioactive agent over a duration from 24 hours to 100 days comprising: and a blend of end-capped uncapped biocompatible, biodegradable poly(lactide/glycolide).
Type:
Grant
Filed:
August 21, 1997
Date of Patent:
September 10, 2002
Assignee:
The United States of America as represented by the Secretary
of the Army
Inventors:
Noelle Christine Vook, Elliott Jacob, Jean A. Setterstrom, John van Hamont, William Vaughan, Ha Duong
Abstract: These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic “inflammatory cascade” process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods.
Abstract: The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.
Type:
Grant
Filed:
May 27, 1993
Date of Patent:
August 27, 2002
Assignee:
Alza Corporation
Inventors:
David Emil Edgren, Gurdish Kaur Bhatti, Zahedeh Hatamkhani, Patrick S. L. Wong
Abstract: The present invention concerns an extended release formulation having an accelerating erosion and/or dissolution rate of the surface of the formulation. The formulation comprises a drug having low solubility in water dispersed or dissolved in at least one erodable hydrophilic polymeric matrix.
Type:
Application
Filed:
February 21, 2001
Publication date:
August 22, 2002
Inventors:
Inger Norden, Catarina Carling, Peter Fyhr
Abstract: A multiple unit oral pharmaceutical dosage form having a plurality of pellets in a water soluble capsule or in a tablet compressed from the pellets, wherein each pellet contains (a) a substantially inert core, (b) an active ingredient layer over the inert core, and containing (i) a pharmacologically active particulate active ingredient, (ii) a nonembedding amount of a binder for adhering the active ingredient over the inert core, and optionally (iii) a pharmaceutically acceptable, inert adjuvant, such as colloidal silica, and (c) a coating over the active ingredient layer for retarding the release of the active ingredient from the active ingredient layer into an aqueous body fluid solvent in situ, the nonembedding amount of the binder is suitably from about 1% wt. to about 10% wt.
Type:
Grant
Filed:
July 8, 1999
Date of Patent:
August 20, 2002
Assignee:
Asto-Medica AG
Inventors:
Helmut Momberger, Marc Raber, Dieter Kuhn, Wolfgang Schmid
Abstract: A drug delivery system provides sustained-release delivery of therapeutic biologically active compounds administered epidurally. In the preferred embodiment the biologically active compound is an opioid, which is encapsulated within the non-concentric internal aqueous chambers or bilayers of multivesicular liposomes. The opioid is released over an extended period of time when the liposomes are introduced epidurally as a single dose for sustained analgesia.
Type:
Grant
Filed:
September 16, 1997
Date of Patent:
August 6, 2002
Assignee:
SkyePharma Inc.
Inventors:
Andres Gruber, Sharad B. Murdande, Taehee Kim, Sinil Kim
Abstract: Controlled quantities of powdered medication are formed in controlled release packages using electrostating metering. Also provided are combination medication therapy delivery packages comprising two or more active pharmaceuticals segregated from one another in a single delivery package.
Abstract: The present invention provides a multi-layered soft capsule for effectively eliminating bad breath, and a method for producing the same. The multi-layered soft capsule (10) for eliminating bad breath of the present invention comprises a first soft capsule composed of a first soft capsule layer (1) and a first soft capsule content (3), and a second soft capsule composed of a second soft capsule layer (2) and a second soft capsule content (4), which is contained in the first soft capsule. Both the contents (3) and (4) contain a component having an effect of eliminating bad breath. The multi-layered soft capsule (10) of the present invention is characterized in that the second soft capsule (2) is solved in a stomach.
Abstract: The present invention relates to capsules encapsulating antibody-producing cells, and to use of such capsules and encapsulated cells, respectively, for implantation in vivo for long term delivery or sustained delivery of antibodies of therapeutic interest.
Type:
Grant
Filed:
June 21, 1999
Date of Patent:
July 30, 2002
Assignees:
Bavarian Nordic Research Institute, Centre National de la Recherche Scientifique
Inventors:
Marc Piechaczyk, Mireia Pelegrin, Mariana Marin, Robert Saller, Brian Salmons
Abstract: Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.
Type:
Application
Filed:
August 14, 2001
Publication date:
July 25, 2002
Inventors:
Kamal K. Midha, Mark Hirsh, Whe-Yong Lo
Abstract: Described herein are methods comprising the oral administration of budesonide for the treatment of ulcerative colitis and Crohn's colitis in its active phase. The methods can also be applied as relapse preventing therapy for Crohn's colitis in its chronic phase and Crohn's disease in the small intestine.
Abstract: A method of producing a free flowing and compressible liquid/power admixture of an active drug substance, by converting the active substance into a liquisolid system. This is accomplished by introducing by the drug into a non-volatile liquid or a mixture of non-volatile and volatile liquids to from a mixture, selecting at least one solid carrier material and admixing these components to produce a non-adherent, free-flowing and compressible liquid/power mass admixture, the amounts of drug and carrier being selected to optimize flow and compressibility.
Abstract: The invention provides a tablet and methods for making the tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating material to modify release of the active agent.
Type:
Grant
Filed:
May 19, 2000
Date of Patent:
July 16, 2002
Assignee:
Yamanouchi Pharmaceutical Co., Ltd.
Inventors:
James S. Chu, Yisong Yang, Joseph A. Fix
Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
Type:
Grant
Filed:
June 19, 2001
Date of Patent:
July 16, 2002
Assignee:
Wyeth
Inventors:
Deborah M. Sherman, John C. Clark, John U. Lamer, Steven A. White
Abstract: A dosage form comprising a gelatin capsule formed with a composite wall and containing a liquid, active agent formulation where the wall comprises a barrier layer formed over the external surface of the gelatin capsule, an expandable layer formed over the barrier layer and a semipermeable layer formed over the expandable layer is described. The dosage forms and methods provide for the conversion of standard gelatin, liquid formulation capsules into controlled, release dosage forms that permit the controlled release of the active agent into the environment of use over time.
Type:
Grant
Filed:
May 25, 2001
Date of Patent:
July 16, 2002
Assignee:
Alza Corporation
Inventors:
Patrick S. -L. Wong, Liang C. Dong, Jiansheng Wan
Abstract: A sustained releasing drug which includes an effective component and a copolymer having a weight-average molecular weight of 1,000 to 100,000 which comprises, as repeating structure units, both of a succinimide unit represented by the structural formula (1)
and a hydroxycarboxylic acid unit represented by the structural formula (2)
wherein R is a methyl group or a hydrogen atom, and a process for preparing a copolymer which comprises a polymerization step of heating a mixture of aspartic acid and a cyclic ester compound.
Abstract: A device for dispensing an active substance to be used in a biological medium, in particular in the rumen of an animal, includes a sealed receptacle for containing the substance, and having at least one opening; a closure for provisionally closing the opening of the receptacle, the closure being maintained closed by at least one biodegradable element such that subsequent to the biological degradation of the element, the closure completely releases the opening.
Abstract: The present invention is directed to an improved sustained release drug delivery device comprising a drug core comprising a polymer coated inner core and an impermeable cup or reservoir.
Abstract: Copolymers of lactide and glycolide with high glycolide content. The average glycolate block length is less then about 3, which allows the copolymer to be soluble in slightly polar solvents such as methylene chloride.
Abstract: The present invention provides novel hydrogel-forming, self-solvating, absorbable polyester copolymers capable of selective, segmental association into compliant hydrogels upon contacting an aqueous environment. Methods of using the novel polyester copolymers of the invention in humans are also disclosed for providing a protective barrier to prevent post-surgical adhesion, treatment of defects in conduits such as blood vessels, and controlled release of a biologically active agent for modulating cellular events such as wound healing and tissue regeneration or therapeutic treatment of diseases such as infection of the periodontium, dry socket, bone, skin, vaginal, and nail infections.